Better Buy: Intercept Pharmaceuticals or Genfit?
Both companies aim to grab a piece of the multi-billion dollar market for treating patients with the liver disease NASH. So, which one should you buy?
GENFIT SPON ADS EACH REP 1 ORD SHS
GNFT
GNFT
$15.19
-$0.28
-1.8%
BATS BZX Real Time Price as of November 21, 2019, 4:00 p.m. EST
View Interactive GNFT Charts
GENFIT SPON ADS EACH REP 1 ORD SHS
News & Analysis: GENFIT SPON ADS EACH REP 1 ORD SHS
Can This NASH Stock Really Double Your Money?
An investment bank analyst thinks this biotech stock is worth more than twice its recent price.
3 Top Small-Cap Biotech Stocks for Aggressive Investors
They're risky, but these up-and-coming biotechs could be tremendous winners for investors willing to take on those risks.
3 Top Stocks That Aren't on Wall Street's Radar
Genfit, Changyou, and Children's Place aren't turning heads on Wall Street quite yet, but that could change very soon.
